{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:29:56Z","timestamp":1790756996352,"version":"4.1.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"am","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.canrad.2023.01.006","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T09:44:54Z","timestamp":1684316694000},"page":"341-348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Limites de la d\u00e9finition des contraintes de dose pour les organes \u00e0 risque sp\u00e9cifiques \u00e0 la radioth\u00e9rapie st\u00e9r\u00e9otaxique"],"prefix":"10.1016","volume":"27","author":[{"given":"A.","family":"Beddok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Loi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Rivin Del Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-L.","family":"Dumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Orthuon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Cr\u00e9hange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2023.01.006_bib0350","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.semradonc.2008.04.001","article-title":"An Overview of hypofractionation and introduction to this issue of Semin Radiat Oncol","volume":"18","author":"Timmerman","year":"2008","journal-title":"Semin Radia Oncol"},{"key":"10.1016\/j.canrad.2023.01.006_bib0355","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.semradonc.2008.04.004","article-title":"The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction","volume":"18","author":"Brenner","year":"2008","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.01.006_bib0360","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.semradonc.2008.04.005","article-title":"The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery","volume":"18","author":"Kirkpatrick","year":"2008","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.01.006_bib0365","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: the report of AAPM Task Group 101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med Phys"},{"key":"10.1016\/j.canrad.2023.01.006_bib0370","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.ijrobp.2017.08.014","article-title":"Hypofractionated stereotactic radiation therapy to the resection bed for intracranial metastases","volume":"99","author":"Keller","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.01.006_bib0375","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.canrad.2017.01.017","article-title":"[Risk of radionecrosis after hypofractionated stereotactic radiotherapy targeting the postoperative resection cavity of brain metastases]","volume":"21","author":"Keller","year":"2017","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2023.01.006_bib0380","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.canrad.2016.06.010","article-title":"Stereotactic radiotherapy following surgery for brain metastasis: predictive factors for local control and radionecrosis","volume":"21","author":"Dor\u00e9","year":"2017","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2023.01.006_bib0385","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.ijrobp.2009.12.061","article-title":"Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system","volume":"79","author":"Levin","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.01.006_bib0390","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.canrad.2020.05.008","article-title":"[What is the place of surgery in the management of brain metastases in 2020?]","volume":"24","author":"Cebula","year":"2020","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2023.01.006_bib0395","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3389\/fonc.2018.00395","article-title":"Diagnosis and management of radiation necrosis in patients with brain metastases","volume":"8","author":"Vellayappan","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.canrad.2023.01.006_bib0400","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3171\/jns.1991.75.2.0177","article-title":"The influence of volume on the tolerance of the brain to radiosurgery","volume":"75","author":"Marks","year":"1991","journal-title":"J Neurosurg."},{"key":"10.1016\/j.canrad.2023.01.006_bib0405","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0360-3016(97)89481-3","article-title":"Complications from arteriovenous malformation radiosurgery: multivariate analysis and risk modeling","volume":"38","author":"Flickinger","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.01.006_bib0410","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S0360-3016(99)00513-1","article-title":"Development of a model to predict permanent symptomatic postradiosurgery injury for arteriovenous malformation patients. Arteriovenous Malformation Radiosurger Study Group","volume":"46","author":"Flickinger","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.01.006_bib0415","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S0360-3016(96)00422-1","article-title":"Risk analysis of linear accelerator radiosurgery","volume":"36","author":"Voges","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.01.006_bib0420","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/STROKEAHA.116.014825","article-title":"Estimating the risks of adverse radiation effects after gamma knife radiosurgery for arteriovenous malformations","volume":"48","author":"Kano","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.canrad.2023.01.006_bib0425","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3171\/2015.9.JNS151311","article-title":"Stereotactic radiosurgery for cerebral arteriovenous malformations: evaluation of long-term outcomes in a multicenter cohort","volume":"126","author":"Starke","year":"2017","journal-title":"J Neurosurg"},{"key":"10.1016\/j.canrad.2023.01.006_bib0430","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0360-3016(01)01757-6","article-title":"Dose conformity of gamma knife radiosurgery and risk factors for complications","volume":"51","author":"Nakamura","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.01.006_bib0435","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0360-3016(99)00507-6","article-title":"Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05","volume":"47","author":"Shaw","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.01.006_bib0440","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3171\/2016.3.JNS153014","article-title":"Impact of the radiosurgery prescription dose on the local control of small (2cm or smaller) brain metastases","volume":"126","author":"Mohammadi","year":"2017","journal-title":"J Neurosurg"},{"key":"10.1016\/j.canrad.2023.01.006_bib0445","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3171\/2014.10.JNS141610","article-title":"Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors","volume":"123","author":"Sneed","year":"2015","journal-title":"J Neurosurg"},{"key":"10.1016\/j.canrad.2023.01.006_bib0450","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ijrobp.2018.10.038","article-title":"Single versus multifraction stereotactic radiosurgery for large brain metastases: an international meta-analysis of 24\u00a0trials","volume":"103","author":"Lehrer","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.01.006_bib0455","doi-asserted-by":"crossref","unstructured":"Blonigen BJ, Lamba MA. Irradiated Volume as a Predictor of Brain Radionecrosis After Linear Accelerator Stereotactic Radiosurgery. 2010;77(4):6.","DOI":"10.1016\/j.ijrobp.2009.06.006"},{"key":"10.1016\/j.canrad.2023.01.006_bib0460","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1259\/bjr\/36606138","article-title":"The relation between various conformity indices and the influence of the target coverage difference in prescription isodose surface on these values in intracranial stereotactic radiosurgery","volume":"85","author":"Ohtakara","year":"2012","journal-title":"Br J Radiol. juin"},{"key":"10.1016\/j.canrad.2023.01.006_bib0465","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1748-717X-6-48","article-title":"Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis","volume":"6","author":"Minniti","year":"2011","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.01.006_bib0470","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ijrobp.2005.07.980","article-title":"12Gy gamma knife radiosurgical volume is a predictor for radiation necrosis in non-AVM intracranial tumors","volume":"64","author":"Korytko","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.01.006_bib0475","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.ijrobp.2017.08.014","article-title":"Hypofractionated stereotactic radiation therapy to the resection bed for intracranial metastases","volume":"99","author":"Keller","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.01.006_bib0480","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijrobp.2020.08.013","article-title":"Single- and multifraction stereotactic radiosurgery dose\/volume tolerances of the brain","volume":"110","author":"Milano","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.01.006_bib0485","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"JCO"},{"key":"10.1016\/j.canrad.2023.01.006_bib0490","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.ijrobp.2009.06.091","article-title":"Radiation dose-volume effects in the lung","volume":"76","author":"Marks","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.canrad.2023.01.006_bib0495","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijrobp.2018.11.028","article-title":"Organs at risk considerations for thoracic stereotactic body radiation therapy: what is safe for lung parenchyma?","volume":"110","author":"Kong","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.01.006_bib0500","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.ijrobp.2010.07.1977","article-title":"Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus","volume":"81","author":"Kong","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.01.006_bib0505","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.prro.2016.01.009","article-title":"Severe radiation pneumonitis after lung stereotactic ablative radiation therapy in patients with interstitial lung disease","volume":"6","author":"Bahig","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.01.006_bib0510","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/02841860802520821","article-title":"Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy","volume":"48","author":"Ricardi","year":"2009","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2023.01.006_bib0515","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.radonc.2010.04.027","article-title":"Dose-response relationship for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy","volume":"97","author":"Guckenberger","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.01.006_bib0520","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.radonc.2010.10.003","article-title":"Treatment of large stage I-II lung tumors using stereotactic body radiotherapy (SBRT): planning considerations and early toxicity","volume":"97","author":"Ong","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.01.006_bib0525","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.ijrobp.2009.10.015","article-title":"Radiation pneumonitis after hypofractionated radiotherapy: evaluation of the LQ(L) model and different dose parameters","volume":"77","author":"Borst","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.01.006_bib0530","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.ijrobp.2014.01.022","article-title":"Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a \u00ab\u00a0no fly zone\u00a0\u00bb","volume":"88","author":"Chang","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.01.006_bib0535","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ijrobp.2015.07.2260","article-title":"A Randomized phase 2\u00a0study comparing 2\u00a0stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer: NRG Oncology RTOG 0915 (NCCTG N0927)","volume":"93","author":"Videtic","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.01.006_bib0540","doi-asserted-by":"crossref","first-page":"945189","DOI":"10.3389\/fonc.2022.945189","article-title":"Outcome of lung oligometastatic patients treated with stereotactic body irradiation","volume":"12","author":"Virbel","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.canrad.2023.01.006_bib0545","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.lungcan.2018.11.013","article-title":"Stereotactic body radiation therapy for stage I non-small cell lung carcinomas: Moderate hypofractionation optimizes outcome","volume":"126","author":"Menoux","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canrad.2023.01.006_bib0550","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.radonc.2013.06.045","article-title":"Lung stereotactic body radiation therapy (SBRT) delivered over 4\u00a0or 11\u00a0days: a comparison of acute toxicity and quality of life","volume":"108","author":"Jain","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.01.006_bib0555","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.radonc.2016.07.026","article-title":"Local control dependence on consecutive vs. nonconsecutive fractionation in lung stereotactic body radiation therapy","volume":"121","author":"Alite","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.01.006_bib0560","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.ijrobp.2016.03.024","article-title":"Simple factors associated with radiation-induced lung toxicity after stereotactic body radiation therapy of the thorax: a pooled analysis of 88\u00a0studies","volume":"95","author":"Zhao","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.01.006_bib0565","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1097\/JTO.0b013e31822e71d8","article-title":"Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer","volume":"6","author":"Haasbeek","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2023.01.006_bib0570","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non\u2013small-cell lung cancer: NRG Oncology\/RTOG 0813\u00a0Trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.01.006_bib0575","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jtho.2016.03.008","article-title":"Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with \u00ab\u00a0ultracentral\u00a0\u00bb non-small cell lung cancer","volume":"11","author":"Tekatli","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2023.01.006_bib0580","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ijrobp.2017.11.022","article-title":"Normal tissue complication probability modeling of pulmonary toxicity after stereotactic and hypofractionated radiation therapy for central lung tumors","volume":"100","author":"Tekatli","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.01.006_bib0585","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ijrobp.2008.08.012","article-title":"Dose distribution analysis in stereotactic body radiotherapy using dynamic conformal multiple arc therapy","volume":"74","author":"Takeda","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.01.006_bib0590","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1002\/cncr.27530","article-title":"Phase 1\/2\u00a0trial of single-session stereotactic body radiotherapy for previously unirradiated spinal metastases","volume":"118","author":"Garg","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2023.01.006_bib0595","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijrobp.2019.09.038","article-title":"Spinal cord dose tolerance to stereotactic body radiation therapy","volume":"110","author":"Sahgal","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.01.006_bib0600","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3\u00a0trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2023.01.006_bib0605","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.urology.2010.01.027","article-title":"Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors","volume":"76","author":"Szymanski","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.canrad.2023.01.006_bib0610","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2010.31.4377","article-title":"Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer","volume":"29","author":"Boike","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.01.006_bib0615","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1016\/j.ijrobp.2012.01.023","article-title":"Pelvic normal tissue contouring guidelines for radiation therapy: a radiation therapy oncology group consensus panel atlas","volume":"83","author":"Gay","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.01.006_bib0620","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.radonc.2014.06.009","article-title":"Dosimetric and patient correlates of quality of life after prostate stereotactic ablative radiotherapy","volume":"112","author":"Elias","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.01.006_bib0625","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3109\/0284186X.2015.1037011","article-title":"Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer","volume":"55","author":"Kole","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2023.01.006_bib0630","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/j.prro.2016.07.004","article-title":"Receiver operating curves and dose-volume analysis of late toxicity with stereotactic body radiation therapy for prostate cancer","volume":"7","author":"Zhang","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.01.006_bib0635","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.radonc.2017.03.006","article-title":"Stereotactic ablative radiotherapy in the treatment of low and intermediate risk prostate cancer: Is there an optimal dose?","volume":"123","author":"Helou","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.01.006_bib0640","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.radonc.2015.12.020","article-title":"Dose-escalation of five-fraction SABR in prostate cancer: toxicity comparison of two prospective trials","volume":"118","author":"Musunuru","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.01.006_bib0645","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/1748-717X-8-256","article-title":"Potency preservation following stereotactic body radiation therapy for prostate cancer","volume":"8","author":"Obayomi-Davies","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.01.006_bib0650","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ijrobp.2009.07.1748","article-title":"Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial","volume":"78","author":"Wiegner","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.01.006_bib0655","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.radonc.2017.03.006","article-title":"Stereotactic ablative radiotherapy in the treatment of low and intermediate risk prostate cancer: Is there an optimal dose?","volume":"123","author":"Helou","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.01.006_bib0660","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3389\/fonc.2014.00301","article-title":"Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7-year study","volume":"4","author":"Katz","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.canrad.2023.01.006_bib0665","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.radonc.2020.05.038","article-title":"Organ at risk delineation for radiation therapy clinical trials: Global Harmonization Group consensus guidelines","volume":"150","author":"Mir","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.01.006_bib0670","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.radonc.2011.08.046","article-title":"The impact of microscopic disease on the tumor control probability in non-small-cell lung cancer","volume":"100","author":"Siedschlag","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.01.006_bib0675","doi-asserted-by":"crossref","first-page":"N267","DOI":"10.1088\/0031-9155\/55\/10\/N01","article-title":"The Hug-Kellerer equation as the universal cell survival curve","volume":"55","author":"Ekstrand","year":"2010","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.canrad.2023.01.006_bib0680","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.canrad.2021.11.001","article-title":"Organs at risk radiation dose constraints","volume":"26","author":"No\u00ebl","year":"2022","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2023.01.006_bib0685","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/ncponc0954","article-title":"Stereotactic radiotherapy for stage I non-small-cell lung cancer-the triumph of technology over biology?","volume":"4","author":"Ball","year":"2007","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.canrad.2023.01.006_bib0345","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41571-021-00501-4","article-title":"Evolution of systemic therapy for stages I\u2013III non-metastatic non-small-cell lung cancer","volume":"18","author":"Chaft","year":"2021","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321823000677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321823000677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:36:58Z","timestamp":1761136618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321823000677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1278321823000677"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2023.01.006","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Limites de la d\u00e9finition des contraintes de dose pour les organes \u00e0 risque sp\u00e9cifiques \u00e0 la radioth\u00e9rapie st\u00e9r\u00e9otaxique","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2023.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}